Publications by authors named "Rachel Courtney"

Claim this Profile
F
Frequency of safety net errors in the emergency department: Effect of patient handoffs.
Joseph S Turner, Rachel D Courtney, Elisa Sarmiento, Timothy J Ellender

Am J Emerg Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Commercial Milk-Specific Lateral Flow Devices.
Rachel C Courtney, Steve L Taylor, Joe L Baumert

J Food Prot· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel homozygous likely-pathogenic intronic variant in INS causing permanent neonatal diabetes in siblings.
Rachel Courtney, Candace Gamble, Monica L Arango, Avni Shah, Nunilo I Rubio

J Pediatr Endocrinol Metab· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
Giovanni Martinelli, Vivian G Oehler, Cristina Papayannidis, Rachel Courtney, M Naveed Shaik

Lancet Haematol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.
Andrew J Wagner, Wells A Messersmith, M Naveed Shaik, Sherry Li, Xianxian Zheng, Rachel Courtney

Clin Cancer Res· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
John P Leonard, Ann S LaCasce, Mitchell R Smith, Ariela Noy, Lucian R Chirieac, Rachel Courtney

Blood· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Keith T Flaherty, Patricia M Lorusso, Angela Demichele, Vandana G Abramson, Rachel Courtney

Clin Cancer Res· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study.
Susan Raber, Rachel Courtney, Tomoko Maeda-Chubachi, Brad D Simons, Sharon F Freedman

Ophthalmology· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Ronald A Schachar, Susan Raber, Rachel Courtney, Min Zhang

Curr Eye Res· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor.
Rachel Courtney, Paul M Stewart, Melvin Toh, Marie-Noella Ndongo, Roberto A Calle

J Clin Endocrinol Metab· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.
Jeremy W Tomlinson, Mark Sherlock, Beverley Hughes, Susan V Hughes, Fiona Kilvington, Rachel Courtney

J Clin Endocrinol Metab· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations.
Farkad Ezzet, David Wexler, Rachel Courtney, Gopal Krishna, Josephine Lim

Clin Pharmacokinet· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition of posaconazole following single-dose oral administration in healthy subjects.
Philip Krieter, Brian Flannery, Timothy Musick, Mark Gohdes, Monika Martinho, Rachel Courtney

Antimicrob Agents Chemother· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men.
Rachel Courtney, Elaine Radwanski, Josephine Lim, Mark Laughlin

Antimicrob Agents Chemother· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.
Rachel Courtney, David Wexler, Elaine Radwanski, Josephine Lim, Mark Laughlin

Br J Clin Pharmacol· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A practical model for preventing type 2 diabetes in minority youth.
Deborah Burnet, Andrea Plaut, Rachel Courtney, Marshall H Chin

Diabetes Educ· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.
Rachel Courtney, Sudhakar Pai, Mark Laughlin, Josephine Lim, Vijay Batra

Antimicrob Agents Chemother· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis